Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
boston blog main
boston top stories
cancer
clinical trials
fda
national
new york blog main
new york top stories
san diego blog main
san diego top stories
texas blog main
texas top stories
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
barry greene
boston
boston university
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
cardiovascular disease
checkpoint inhibitors
colorectal cancer
ctla-4
ctla-4 inhibitor
dan ollendorf
detroit blog main
detroit top stories
drugs
eisai
europe blog main
europe top stories
hereditary transthyretin amyloidosis
What
medicine
3
×
patients
3
×
cancer
fda
ago
allison
alnylam
approve
awaits
biological
cancers
countless
crossed
decades
decision
discovered
drug
eisai
fight
fingers
flags
friday
harnessing
higher
historic
honjo
honors
immune
immunotherapy
incidence
lives
lorcaserin
loss
market
marketing
nobel
pioneers
post
prize
pulls
Language
unset
Current search:
medicine
×
patients
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
